GlobeNewswire Inc.··Glucotrack, Inc.Glucotrack Narrows Losses, Advances Glucose Monitor Tech Toward FDA Trials
Glucotrack narrowed net losses to $19.4M in 2025 while advancing implantable glucose monitor toward FDA trials in H2 2026.
GCTKFDA approvalclinical trials